Mr. Bruce Booth | Partner
Atlas Ventures

Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005. He focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail, Sept 2008), Proprius (acquired by Cypress Biosciences, Feb 2008), and Stromedix. Previously, Bruce was a Principal at Caxton Health Holdings L.L.C. Prior to Caxton, he was an Associate Principal at McKinsey & Company. Bruce earned a Doctorate in Molecular Immunology from the Oxford University. He received his Bachelor of Science degree in Biochemistry from the Pennsylvania State University. He serves as a Trustee of the New York Academy of Medicine. He also currently serves in several life sciences advisory roles, including UCB Pharma, Beth Israel Deaconess Medical Center's Accelerating Bench to Bedside effort, and LifeTech Boston. Bruce has also authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology and Nature Reviews Drug Discovery.